[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Anzhen Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":636},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,88,0,25,[9,44,68,92,127,154,178,204,227,249,266,288,318,341,364,388,412,434,456,479,497,525,550,587,613],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632789","comparison-of-femorofemoral-bypass-and-left-heart-bypass-techniques-in-open-thoracoabdominal-aortic-aneurysm-repair-100632789",false,"NCT07518251","CompaRison of FEmorofemoral Bypass and Left-Heart ByPass Techniques in Open Thoracoabdominal AortIc Aneurysm Repair","Comparison of Femorofemoral Bypass and Left-Heart Bypass Techniques in Open Thoracoabdominal Aortic Aneurysm Repair: A Study Protocol for Multicenter, Two-Arm, Open-Label, Randomized, ParalleI-Controlled Non-Inferiority Trial","REPAIR","Inclusion Criteria:\n\n1. Computed tomography angiography (CTA) confirmed as ATAAD according to the 2022 ACC\u002FAHA Guideline for the Diagnosis and Management of Aortic Disease;\n2. Adult patients (≥18 years old);\n3. Indications for TAAAR are available and requiring cardiopulmonary bypass;\n4. Signed informed consent and availability for follow-up.\n\nExclusion Criteria:\n\n1. History of chronic renal failure, chronic heart failure, Coronary heart disease with established surgical indications, hepatocirrhosis, and hepatic insufficiency;\n2. History of severe cerebral infarction (with cerebral infarction sequels);\n3. Inflammatory aortic diseases, such as Takayasu arteritis and Behçet's disease, etc;\n4. History of infectious aortic diseases;\n5. History of malignancy or previous radiotherapy;\n6. Pregnant or feeding women, or anyone planning to reproduce during the test period;\n7. Participating in any other clinical trial;\n8. Having other causes not eligible for operation.","ALL","18 Years",{"count":21,"type":22},236,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study is a multicenter, two-arm, open-label, randomized, parallel-controlled trial, which plans to enroll 236 participants diagnosed with TAAA from 4 hospitals in China. All patients receive TAAAR procedure and are randomized to control group (LHB) and experimental group (fCPB) in the ratio of 1:1. After a 1-year follow-up, the validity and safety of the different cardiopulmonary bypass for TAAAR is evaluated via the incidence of major adverse events including surgical mortality, RRT, stroke, and SCI, as well as intraoperative blood product transfusion volume, mechanical ventilation, and early mortality.",[28,29,30],"Thoracoabdominal Aortic Aneurysm","Cardiopulmonary Bypass","Open Repair","RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2026-03-06",{"date":39,"type":22},"2028-08",{"name":41,"class":42},"Beijing Anzhen Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100624556","wearable-device-assisted-remote-management-in-atrial-fibrillation-complicated-by-heart-failure-warm-hf-trial-100624556","NCT07411170","Wearable Device-Assisted Remote Management in Atrial Fibrillation Complicated by Heart Failure: WARM-HF Trial","Wearable Device-assisted Remote Management for Patients With Atrial Fibrillation Complicated by Heart Failure: A Prospective, Open-label, Multi-center, Randomized Controlled Trial","WARM-HF","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Subjects diagnosed with acute decompensated heart failure (ADHF) :1)Heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40%;2)New York Heart Association (NYHA) functional class II-IV;3)NT-proBNP \\> 2500 pg\u002FmL or BNP \\> 600 pg\u002FmL\n3. Atrial fibrillation (AF) diagnosed during hospitalization (documented AF episode lasting \\> 30 seconds on electrocardiogram \\[ECG\\] within the past 12 months)\n\nExclusion Criteria:\n\n1. Intolerance to heart failure pharmacotherapy\n2. Severe anemia, uncorrected thyroid disease\n3. ST-segment elevation myocardial infarction (STEMI) within 3 months\n4. Known complex congenital\u002Fsecondary heart disease; infiltrative cardiomyopathy (e.g., cardiac amyloidosis, sarcoidosis, lymphoma, or endomyocardial fibrosis); myocarditis; constrictive pericarditis; cardiac tamponade; hypertrophic cardiomyopathy; stress cardiomyopathy (Takotsubo cardiomyopathy); or uncorrected primary valvular heart disease requiring surgical intervention.\n5. Previous or planned major cardiac surgery or mechanical circulatory support within 6 months, including coronary artery bypass grafting, cardiac valve repair or replacement, ventricular assist device or mechanical circulatory support device implantation, and heart transplantation.\n6. Current use of or planned implantation of a pacemaker.\n7. Contraindications to wearing a smartwatch (e.g., limb disability or known allergy to rubber\u002Fmetal materials)\n8. Inability to access the Internet or lack of proficiency in operating smart devices\n9. Pregnant or lactating women\n10. Organ transplantation within the past 12 months\n11. Expected survival time of less than 1 year for any reason\n12. Refusal to participate or inability to comply with follow-up requirements\n13. Deemed ineligible for participation in the study by the investigators",{"count":53,"type":22},400,[25],"Patients with acute decompensated heart failure (HF) have a significantly high risk of death and HF re-hospitalization during the vulnerable phase post discharge. Therefore, early post-discharge management is crucial, and the cornerstone of HF treatment-particularly for HF with reduced ejection fraction (HFrEF)-is guideline-directed medical therapy (GDMT), a comprehensive pharmacotherapeutic strategy supported by robust clinical evidence. Timely titration of GDMT, especially within the first few weeks after discharge, has been shown to improve clinical outcomes, reduce readmissions, and enhance long-term prognosis. However, ensuring optimal follow-up and therapeutic adjustments remains a major challenge in real-world practice. Atrial fibrillation (AF) is a common comorbidity in patients with HF, especially in those with severe HF. The presence of AF significantly complicates the clinical course and worsens the prognosis of HF.\n\nAdvances in wearable technology have made continuous, non-invasive monitoring of vital signs, arrhythmia burden, and physical status increasingly feasible. Devices such as smartwatches and ECG belts can provide real-time physiological data, offering new opportunities for remote and proactive disease management. Despite the growing availability of such data, the complex interplay between AF and HF demands highly personalized management. Currently, there is a lack of high-quality clinical evidence on how to effectively integrate wearable device data into personalized strategies for this specific patient population.\n\nThis is an open-label, multi-center, endpoint-blinded, parallel-group randomized clinical trial supported by the American Heart Association. The primary objective is to determine whether wearable device-assisted digital consultations can optimize GDMT in patients with AF complicated by acute decompensated HF. The study plans to enroll 400 participants, who will be randomly assigned to either a wearable device-assisted intervention group or a conventional treatment control group. The primary endpoint is the change in HF GDMT score 3 months after randomization.\n\nApple Inc. provided funding, devices, and technical support for this study. Apple was not a sponsor of the trial and was not involved in its execution, data analysis, interpretation, or manuscript preparation.",[57,58],"HFrEF - Heart Failure With Reduced Ejection Fraction","AF - Atrial Fibrillation","NOT_YET_RECRUITING","2026-06-25",{"date":62,"type":35},"2026-06-29",{"date":64,"type":22},"2026-08",{"date":66,"type":22},"2028-09",{"name":41,"class":42},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":43},"100641153","modifiable-risk-factors-for-cognitive-dysfunction-in-patients-with-coronary-heart-disease-100641153","NCT07657624","Modifiable Risk Factors for Cognitive Dysfunction in Patients With Coronary Heart Disease","Association Between Modifiable Risk Factors and Cognitive Function in Patients With Coronary Heart Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Diagnosis of coronary heart disease (meeting at least one of the following):\n\n   * Coronary angiography or coronary CTA showing ≥50% stenosis in ≥1 major coronary artery;\n   * Established diagnosis of coronary heart disease with prior medical, interventional, or surgical treatment;\n   * Objective evidence of myocardial ischemia or typical clinical symptoms\n3. Completion of standardized neuropsychological assessment during hospitalization\n4. Completion of metabolic marker evaluation (fasting glucose, insulin, HbA1c, etc.) and agreement to undergo relevant imaging and functional assessments\n5. Provision of signed written informed consent\n\nExclusion Criteria:\n\n1. Previously diagnosed dementia.\n2. History of stroke, cerebral hemorrhage, or other central nervous system diseases known to cause cognitive impairment.\n3. Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).\n4. Pregnancy or breastfeeding.",{"count":76,"type":22},2352,"OBSERVATIONAL","This prospective observational study aims to investigate the association between risk factors and cognitive function in patients with coronary heart disease (CHD), and to explore the underlying mechanisms involving metabolic parameters and multimodal imaging features. A total of 2,352 participants will be enrolled from Beijing Anzhen Hospital, Capital Medical University, China. Eligible participants are adults (≥18 years) with confirmed CHD who undergo systematic neuropsychological assessment during hospitalization. Comprehensive assessments include cognitive function tests (MMSE, MoCA, BCAT, AD8), metabolic evaluations (fasting glucose, insulin, HbA1c, ceramides), coronary computed tomography angiography (CCTA), cardiac magnetic resonance (CMR), sleep respiratory monitoring, and frailty and psychological assessments.The primary outcome is cognitive impairment. The study will identify potential risk factors and provide insights into early identification and personalized intervention strategies for cognitive decline in CHD patients.",[80,81],"Coronary Heart Disease","Cognitive Impairment, Mild",[83,84,80],"Risk Factors","Cognitive Impairment","2026-06-15",{"date":87,"type":35},"2026-06-18",{"date":32,"type":22},{"date":90,"type":22},"2031-05-01",{"name":41,"class":42},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":112,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100627110","start-cpap-therapy-in-obstructive-sleep-apnea-patients-after-atrial-fibrillation-ablation-100627110","NCT07444372","Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation","Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation: A Multicenter, Open-label, Randomized Clinical Trial","STOP-AFib","Inclusion Criteria:\n\nPatients must meet all of the following conditions to be eligible for the study:\n\n* Age 18-75 years.\n* Patients with persistent AF scheduled for first-time catheter ablation.\n* Diagnosed with OSA.\n* Able to tolerate CPAP therapy.\n* Capable of understanding and complying with the study protocol.\n* Willing to sign the informed consent form.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from the study:\n\n* Secondary AF.\n* Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).\n* Left ventricular ejection fraction \\\u003C 30%.\n* Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).\n* Pregnant or breastfeeding women.\n* History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.\n* History of stroke or transient ischemic attack within 6 months prior to screening.\n* Perioperative complications related to the ablation procedure occurring prior to randomization.\n* Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.\n* Life expectancy \\\u003C 1 year.\n* Central sleep apnea.\n* Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI \\> 30kg\u002Fm² and awake PaCO₂ \\> 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with \\> 1 episode of respiratory failure or hypercapnia.\n* Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.\n* Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.\n* Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.\n* Current participation in other drug or device trials.","75 Years",{"count":102,"type":22},658,[25],"Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.\n\nThis study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.\n\nParticipants will:\n\n* Be randomly assigned to either the CPAP group or the usual care group.\n* If in the CPAP group, use a CPAP device for 12 months.\n* Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months post-operation.\n* Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after their procedure.",[106,107,108,109,110,111],"Obstructive Sleep Apnea","Sleep Disorder (Disorder)","Atrial Fibrillation (AF)","Sleep Disordered Breathing (SDB)","Arrhythmia","Continuous Positive Airway Pressure",[106,111,113,114,115,116,117],"Atrial Fibrillation","Ablation of atrial fibrillation","Sleep Disordered Breathing","Clinical Trial","Catheter Ablation","2026-06-14",{"date":120,"type":35},"2026-06-16",{"date":122,"type":35},"2026-05-12",{"date":124,"type":22},"2029-01-31",{"name":41,"class":42},27,{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":43},"100643371","cohort-study-of-postoperative-cognitive-dysfunction-after-off-pump-coronary-artery-bypass-grafting-100643371","NCT07643194","Cohort Study of Postoperative Cognitive Dysfunction After Off-Pump Coronary Artery Bypass Grafting","Risk of Postoperative Cognitive Dysfunction After Off-Pump Coronary Artery Bypass Grafting: A Prospective Cohort Study","OPCAB-POCD","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled to undergo elective off-pump coronary artery bypass grafting\n* American Society of Anesthesiologists physical status classification I to IV\n* Able to complete preoperative cognitive assessments, including the Mini-Mental State Examination and the Montreal Cognitive Assessment\n* Written informed consent provided by the patient or family member\n\nExclusion Criteria:\n\n* Emergency surgery\n* Pre-existing diagnosed cognitive impairment or history of psychiatric disease\n* Preoperative cognitive impairment\n* Severe neurological disease, such as sequelae of stroke, that may interfere with cognitive assessment\n* Severe visual or hearing impairment that prevents completion of cognitive assessment\n* Inability to understand Chinese or presence of language communication barriers",{"count":136,"type":22},600,"This prospective cohort study aims to investigate postoperative cognitive dysfunction in patients undergoing off-pump coronary artery bypass grafting. Eligible patients will be enrolled before surgery and followed after surgery. Cognitive function will be assessed using the Montreal Cognitive Assessment before surgery and at predefined postoperative time points. Perioperative clinical information, including preoperative assessment data, intraoperative monitoring parameters, and postoperative clinical data, will be collected. The study will evaluate the occurrence of postoperative cognitive dysfunction and explore its association with perioperative factors.",[139],"Postoperative Cognitive Dysfunction (POCD)",[141,142,143,144,145],"Postoperative Cognitive Dysfunction","Off-Pump Coronary Artery Bypass Grafting","OPCABG","Montreal Cognitive Assessment","Prospective Cohort Study","2026-06-09",{"date":148,"type":35},"2026-06-11",{"date":150,"type":22},"2026-05-24",{"date":152,"type":22},"2026-12-15",{"name":41,"class":42},{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100641036","phase-2-all-trans-retinoic-acid-for-the-treatment-of-hemophagocytic-lymphohistiocytosis-100641036","NCT07626398","All-Trans Retinoic Acid for the Treatment of Hemophagocytic Lymphohistiocytosis","An Open-Label Study Evaluating the Safety and Efficacy of All-Trans Retinoic Acid in Patients With Hemophagocytic Lymphohistiocytosis","* Inclusion Criteria\n\n  1. Age ≥18 years.\n  2. Patients diagnosed with active hemophagocytic lymphohistiocytosis according to HLH-2004 diagnostic criteria or the investigator's clinical assessment.\n  3. Newly diagnosed or treatment-naïve active HLH requiring initial HLH-directed therapy.\n  4. Presence of active disease manifestations, including at least one of the following: persistent fever, cytopenia, hyperferritinemia, splenomegaly, hypofibrinogenemia and\u002For hypertriglyceridemia, elevated soluble CD25, hemophagocytosis, reduced or absent NK-cell activity, or other HLH-related organ involvement.\n  5. Eastern Cooperative Oncology Group performance status of 0-3, or performance status considered acceptable by the investigator in the context of active HLH.\n  6. Adequate ability to receive oral medication, or ability to receive ATRA through an appropriate enteral route.\n  7. Expected survival of more than 48 hours in the judgment of the investigator.\n  8. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use effective contraception during treatment and for an appropriate period after the last dose of ATRA.\n  9. Ability to understand and willingness to sign written informed consent. For patients unable to provide consent because of disease severity, consent may be provided by a legally authorized representative according to local regulations.\n* Exclusion Criteria\n\n  1. Prior systemic HLH-directed therapy for the current HLH episode, including etoposide-based therapy, ruxolitinib, emapalumab, alemtuzumab, PD-1 blockade, or other investigational HLH-directed treatment. Short-term corticosteroids, supportive care, anti-infective therapy, or emergency treatment before enrollment may be allowed at the investigator's discretion.\n  2. Known hypersensitivity to all-trans retinoic acid, tretinoin, retinoids, or any component of the study drug.\n  3. Pregnant or breastfeeding women.\n  4. Patients with acute promyelocytic leukemia or other diseases for which ATRA is being used as standard leukemia-directed therapy.\n  5. Severe uncontrolled infection, shock, respiratory failure, bleeding, or organ failure that, in the investigator's judgment, would make participation unsafe or prevent assessment of study treatment.\n  6. Severe hepatic dysfunction not primarily attributed to HLH, such as total bilirubin or transaminase levels considered unsafe for ATRA administration by the investigator.\n  7. Severe renal dysfunction requiring dialysis before enrollment, unless considered related to HLH and acceptable by the investigator.\n  8. Active intracranial hypertension, pseudotumor cerebri, or uncontrolled severe neurologic disease that may increase the risk of ATRA-related toxicity.\n  9. Uncontrolled hypertriglyceridemia or other metabolic abnormality that, in the investigator's judgment, would make ATRA treatment unsafe.\n  10. Concomitant use of vitamin A supplements, other systemic retinoids, or medications with unacceptable interaction risk that cannot be discontinued.\n  11. Any other condition that, in the investigator's judgment, would interfere with patient safety, protocol compliance, or interpretation of study results.","65 Years",{"count":163,"type":22},30,[165,166],"PHASE2","PHASE3","This study is designed to evaluate the safety and preliminary efficacy of all-trans retinoic acid (ATRA) as an initial treatment for patients with active hemophagocytic lymphohistiocytosis (HLH). HLH is a severe hyperinflammatory syndrome caused by excessive activation of immune cells and uncontrolled cytokine release. Current treatment often requires intensive immunosuppressive or cytotoxic therapy, which may be associated with significant toxicity.\n\nATRA is an orally available agent that has been widely used in other hematologic diseases and has immunomodulatory effects. Preclinical studies suggest that ATRA may help control HLH-related inflammation and improve immune dysregulation. In this study, patients with newly diagnosed or treatment-naïve active HLH will receive ATRA-based initial therapy. The study will assess clinical response, changes in HLH-related inflammatory markers, organ function, viral or disease-related parameters when applicable, and treatment-related adverse events.\n\nThe goal of this study is to determine whether ATRA can provide a safe and feasible initial therapeutic approach for active HLH and support further clinical development of ATRA-based treatment strategies in this disease.",[169],"Hemophagocytic Lymphohistiocytosis (HLH)","2026-06-02",{"date":172,"type":35},"2026-06-04",{"date":174,"type":22},"2026-06-01",{"date":176,"type":22},"2029-06-01",{"name":41,"class":42},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":186,"targetDuration":188,"studyType":77,"phases":4,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},"100594859","complex-arrhythmia-registry-100594859","NCT07024927","Complex Arrhythmia Registry","Complex Arrhythmia Registry（CAR）： Long-term Outcomes of Catheter Ablation for Atrial Fibrillation or Ventricular Tachycardia： A Multicenter， Prospective Cohort Study","CAR","1. Atrial Fibrillation (AF) Cohort:\n\n   * Inclusion Criteria (Patients must meet ALL of the following criteria):\n\n     1. Age ≥ 18 years.\n     2. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).\n     3. Scheduled to undergo first-time catheter ablation for AF.\n     4. Procedure to be performed using a 3D mapping system.\n     5. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.\n   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):\n\n     1. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).\n     2. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).\n     3. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment\u002Fprocedure.\n     4. Severe active infection (e.g., septic shock, sepsis).\n     5. Contraindications to anticoagulation therapy.\n     6. Current participation in another interventional clinical trial that may confound the results of this study.\n     7. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.\n2. Ventricular Tachycardia (VT) Cohort\n\n   * Inclusion Criteria (Patients must meet ALL of the following criteria):\n\n     1. Age ≥ 18 years.\n     2. Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:\n     3. Ischemic heart disease (e.g., prior MI, coronary artery disease).\n     4. Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)).\n     5. Scheduled to undergo first-time catheter ablation for VT.\n     6. Procedure to be performed using a 3D mapping system.\n     7. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.\n   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):\n\n     1. VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance).\n     2. Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease).\n     3. Cardiac surgery within 60 days prior to the planned ablation procedure.\n     4. Severe coagulopathy (e.g., platelet count \\\u003C 50 x 10⁹\u002FL, disseminated intravascular coagulation (DIC)).\n     5. Severe heart failure with left ventricular ejection fraction (LVEF) \\\u003C 20%.\n     6. Severe active infection (e.g., septic shock, sepsis).\n     7. Current participation in another interventional clinical trial that may confound the results of this study.\n     8. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.",{"count":187,"type":22},4000,"3 Years","This is a prospective, non-randomized, multicenter observational registry study designed to systematically evaluate the long-term efficacy and safety of catheter ablation for treating atrial fibrillation (AF) and ventricular tachycardia (VT) in Chinese patients.",[108,191],"Ventricular Tachycardia (VT)",[193,194,195,196],"atrial fibrillation","ventricular tachycardia","ablation","registry study",{"date":172,"type":35},{"date":199,"type":35},"2025-10-21",{"date":201,"type":22},"2032-06",{"name":41,"class":42},2,{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":211,"sex":18,"minAge":19,"maxAge":100,"enrollmentInfo":212,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":224,"leadSponsor":226,"locationsCount":4},"100637999","correlation-and-prognostic-value-of-body-composition-cardiac-structure-and-function-in-patients-with-different-heart-failure-subtypes-100637999","NCT07619222","Correlation and Prognostic Value of Body Composition, Cardiac Structure and Function in Patients With Different Heart Failure Subtypes","Study on the Correlation and Prognostic Value of Body Composition, Cardiac Structure and Function in Patients With Different Subtypes of Heart Failure","Inclusion Criteria:\n\n1. Meeting the diagnostic criteria for heart failure set forth in the 2022 ESC Guidelines: presence of typical symptoms (e.g., dyspnea, fatigue, edema, etc.) and signs (e.g., pulmonary rales, jugular venous distention, third heart sound, etc.) of heart failure;\n2. Undergoing both coronary computed tomography angiography (CCTA) and non-contrast chest computed tomography (CT), with image quality meeting the requirements for quantitative analysis;\n3. Age ≥ 18 years, with complete clinical and follow-up data, and ability to cooperate with imaging examinations and follow-up assessments.\n\nExclusion Criteria:\n\n1. Acute myocardial infarction occurring within 3 months prior to the imaging examination;\n2. Other definite structural heart diseases, including congenital heart disease, myocarditis, pericardial disease, severe valvular heart disease, etc.;\n3. End-stage organ diseases (hepatic\u002Frenal\u002Fpulmonary failure, active malignancy);\n4. Unmeasurable scan images (e.g., due to pericardial effusion or artifacts);\n5. Incomplete or missing clinical data.",true,{"count":213,"type":22},1000,"Heart failure (HF) refers to impaired cardiac function caused by various heart diseases. Patients commonly present with dyspnea, fatigue, edema and other symptoms, ranking among the leading causes of death from cardiovascular diseases worldwide. According to World Health Organization statistics, more than 26 million people globally suffer from heart failure. The rising prevalence of aging population, hypertension, diabetes and other comorbidities continues to expand the patient population, imposing a heavy burden on families and society.\n\nBody mass index (BMI) was traditionally adopted to assess the correlation between obesity and heart failure, yet this method has inherent limitations. The obesity paradox indicates that obese heart failure patients may achieve better recovery outcomes than those with normal weight. Additionally, BMI fails to differentiate the impacts of adipose tissues distributed in distinct anatomical sites. Advances in imaging technology have enabled accurate quantification of regional fat deposits, including epicardial adipose tissue (EAT), subcutaneous adipose tissue (SAT) and intramuscular adipose tissue (IMAT).\n\nDomestic and international studies have verified that fat distribution exerts greater influence than total fat volume. Directly adjacent to the myocardium, EAT may secrete inflammatory mediators and induce myocardial injury. SAT produces protective bioactive substances, while its effects vary across heart failure subtypes and remain inconclusive. IMAT is correlated with reduced physical activity and poor clinical prognosis. Nevertheless, most existing researches focus solely on single-site fat tissue or specific heart failure types. Comprehensive combined analysis of cardiac, somatic and muscular adipose tissues, as well as systematic comparison among diverse heart failure subtypes, remains insufficient.\n\nThis study intends to quantify the three types of adipose tissues simultaneously, combined with cardiac structural and functional examinations, to explore their associations with heart failure. The findings are expected to facilitate precise risk stratification and individualized therapeutic strategy formulation for clinicians.",[216],"Heart Failure",[218,219,220],"heart failure","body composition","cardiac MRI",{"date":222,"type":35},"2026-06-03",{"date":174,"type":22},{"date":225,"type":22},"2028-06-01",{"name":41,"class":42},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":211,"sex":18,"minAge":234,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":4},"100639905","effectiveness-of-patch-electrocardiogram-recorders-in-screening-for-atrial-fibrillation-in-elderly-people-in-the-chinese-community-100639905","NCT07627672","Effectiveness of Patch-Electrocardiogram Recorders in Screening for Atrial Fibrillation in Elderly People in the Chinese Community","Effectiveness of Patch-Electrocardiogram Recorders in Screening for Atrial Fibrillation in Elderly People in the Chinese Community: A Prospective Multicenter Study","Inclusion Criteria:\n\n* Age ≥60 years\n* No prior diagnosis of atrial fibrillation\n* Able to understand the study purpose and willing to provide written informed consent\n* No severe cardiac disease, acute illness, or contraindication to ECG monitoring\n* Able to wear the patch ECG device and comply with continuous monitoring requirements\n\nExclusion Criteria:\n\n* Severe cognitive impairment or inability to cooperate with follow-up assessments\n* Pregnant or breastfeeding women\n* Previously diagnosed with atrial fibrillation and already receiving treatment","60 Years",{"count":236,"type":22},30000,[25],"This prospective, multicenter, single-arm study evaluates the effectiveness of a single-lead patch electrocardiogram (ECG) recorder in screening for atrial fibrillation (AF) among community-dwelling elderly individuals aged ≥60 years in China. Participants will undergo 7 days of continuous ECG monitoring, followed by annual follow-up for up to 10 years to assess long-term outcomes including stroke, heart failure, and death.",[113],[241],"Atrial fibrillation; AF screening; Patch ECG; Wearable ECG; Elderly; Community screening; China; FINDING-AF","2026-05-31",{"date":172,"type":35},{"date":245,"type":22},"2026-09-01",{"date":247,"type":22},"2036-09-30",{"name":41,"class":42},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":211,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":257,"conditions":258,"keywords":259,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":264,"leadSponsor":265,"locationsCount":43},"100640338","prospective-study-on-the-effectiveness-and-safety-of-bi-polar-pulse-field-tip-catheter-ablation-for-atrial-fibrillation-in-chinapotential-af-100640338","NCT07627685","Prospective Study on the Effectiveness and Safety of Bi-polar Pulse-field Tip-catheter Ablation for Atrial Fibrillation in China（POTENTIAL-AF）","POTENTIAL-AF","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Symptomatic paroxysmal AF or persistent AF:\n\n   * Paroxysmal AF: self-terminating within ≤ 7 days; ≥ 2 symptomatic episodes in the 6 months prior to enrolment; ≥ 1 ECG or Holter-documented AF episode in the 12 months prior to enrolment\n   * Persistent AF: duration \\> 7 days and \\\u003C 1 year; ≥ 1 symptomatic episode in the 6 months prior; documented by Holter or 2 ECGs ≥ 7 days apart within 12 months prior\n3. Failure of AAD therapy: inadequate efficacy and\u002For intolerance to ≥ 1 Class I or Class III antiarrhythmic drug\n4. Planned PFA catheter ablation for AF\n5. Voluntary participation with written informed consent Willing and able to comply with study procedures and follow-up (including in-hospital assessment, 30-day and 90-day follow-up)\n\nExclusion Criteria:\n\n1. AF attributable to a reversible cause (e.g., hyperthyroidism, peri-operative or cardiac\u002Fthoracic surgery-related AF)\n2. Concomitant condition with expected survival \\\u003C 1 year (e.g., advanced malignancy)",{"count":236,"type":22},"POTENTIAL-AF is a prospective, multicentre, observational registry study evaluating the real-world effectiveness and safety of bi-polar pulse-field tip-catheter ablation (PFA) for atrial fibrillation (AF) in China. The study will enrol 30,000 adult patients with symptomatic paroxysmal or persistent AF who have failed at least one antiarrhythmic drug (Class I or III) and are planned to undergo PFA using the Jinjiang LEAD-PFA system with PulsedFA catheter at participating centres across China.\n\nAll procedural decisions, including energy settings, ablation targets, and peri-procedural management, are made by the treating physician per routine clinical practice. The study prospectively collects baseline clinical characteristics, intraoperative ablation parameters, and follow-up outcomes at 3 months, 6 months, 12 months, and every 6 months thereafter, for up to 10 years.\n\nThe primary endpoint is all-cause mortality at 10 years. Secondary endpoints (observed over 5 years) include ischaemic stroke, haemorrhagic stroke, transient ischaemic attack (TIA), cardiovascular death, cardiovascular hospitalisation, systemic embolism, thromboembolic death, major bleeding, and clinically relevant non-major bleeding (CRNMB).\n\nBy capturing large-scale, standardised, long-term data across diverse Chinese centres, POTENTIAL-AF aims to describe real-world procedural practice patterns, identify predictors of clinical outcomes, and provide evidence to support the safe and effective application of the Jinjiang bi-polar tip PFA catheter in Chinese AF patients.",[113],[260,117,261],"Pulsed Field Ablation","Pulmonary Vein Isolation",{"date":172,"type":35},{"date":245,"type":22},{"date":247,"type":22},{"name":41,"class":42},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":161,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":287},"100640759","phase-4-effect-of-the-traditional-chinese-medicine-yufeng-ningxin-in-patients-with-hypertension-100640759","NCT07607275","Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension","Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension: a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Male and female participants aged 18-65 years;\n2. Newly diagnosed, untreated hypertension or treated hypertension with a seated systolic blood pressure of 140-159 mmHg and a daytime mean ambulatory systolic blood pressure ≥135 mmHg, following a ≥2-week washout of background antihypertensive medications;\n3. The patient is capable of understanding the study requirements, is willing and able to comply with study procedures, and has provided written informed consent.\n\nExclusion Criteria:\n\n1. Secondary hypertension (including, but not limited to, renovascular hypertension, pheochromocytoma, primary aldosteronism, Cushing syndrome, aortic coarctation, or due to known history of moderate-to-severe obstructive sleep apnea);\n2. Orthostatic hypotension (symptomatic or asymptomatic);\n3. Participation in another hypertension-related clinical trial at enrollment or within 6 months prior;\n4. Currently taking, taken within 30 days prior to randomization, or anticipated to receive during the study treatment period any medication or herbal supplement known to significantly affect blood pressure (with the exception of medications for the treatment of essential hypertension). These drugs include, but are not limited to: organic nitrates, glucocorticoids (excluding topical or inhaled corticosteroids), central nervous system stimulants (e.g., methylphenidate, dexmethylphenidate, amphetamines), estrogens, monoamine oxidase inhibitors, digitalis preparations, Chinese proprietary medicines (such as Tianma Gouteng Granules, Songling Xuemaikang Capsules, Yangxue Qingnao Granules), and herbal medicines (including Salvia miltiorrhiza, Uncaria rhynchophylla, Ginkgo biloba leaves, Prunella vulgaris, etc.);\n5. Users of prescription non-steroidal anti-inflammatory drugs (NSAIDs); initiation of, changes to, or discontinuation of sodium-glucose co-transporter (SGLT2) inhibitor therapy within 4 weeks prior to screening. Patients who were stably taking an SGLT2 inhibitor or low-dose aspirin (defined as ≤100mg per day) for at least 4 weeks prior to screening with no anticipated changes during the study are permitted;\n6. Severe hepatic or renal diseases (ALT \\>3 times the upper limit of normal value, or end stage renal disease on dialysis, or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2);\n7. Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c\\>9.0%);\n8. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack \\[TIA\\]);\n9. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months;\n10. Sustained atrial fibrillation or arrhythmias interfering with electronic BP measurement;\n11. NYHA class III-IV heart failure, or hospitalization for chronic heart failure exacerbation within the past 6 months;\n12. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period;\n13. Dilated cardiomyopathy, hypertrophic cardiomyopathy, rheumatic heart disease, or congenital heart disease;\n14. Other severe diseases that may affect participant enrollment or survival, such as malignancy or acquired immunodeficiency syndrome (AIDS);\n15. Cognitive impairment or severe neuropsychiatric comorbidities that render the patient incapable of providing informed consent;\n16. Participants preparing for or under pregnancy and\u002For lactation;\n17. Frequent night-shift work, with primary working hours during nighttime (e.g., 8:00 PM to 8:00 AM);\n18. Other conditions deemed inappropriate for participation by the investigators.",{"count":274,"type":22},350,[276],"PHASE4","Yufeng Ningxin, a traditional Chinese medicine, has demonstrated potential antihypertensive effects in animal studies and small clinical trials, but has not yet been rigorously evaluated in large randomized clinical trials. Here, the investigators conducted a double-blind, randomized controlled trial to assess the efficacy and safety of Yufeng Ningxin tablets in patients with hypertension.",[279,280],"Hypertension","Essential (Primary) Hypertension","2026-05-29",{"date":170,"type":35},{"date":284,"type":22},"2026-05-15",{"date":225,"type":22},{"name":41,"class":42},16,{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":306,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100637367","phase-2-effect-of-guanxinning-tablet-on-coronary-microcirculation-after-primary-percutaneous-coronary-intervention-in-patients-with-acute-myocardial-infarction-100637367","NCT07621107","Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","A Randomized Explorative Pre-trial of the Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Age between 18 and 80 years (gender is not restricted).\n* STEMI diagnosed for the first time and with an onset time within 12 hours. (According to the \"Chinese Guidelines for the Diagnosis and Treatment of Acute ST - Segment Elevation Myocardial Infarction 2019\" and the fourth - edition \"Global Definition of Myocardial Infarction\" criteria, myocardial infarction refers to acute myocardial injury \\[serum cardiac troponin (cTn) increases and\u002For decreases, and at least once is higher than the upper limit of the normal value (the 99th percentile of the upper limit of the reference value)\\], along with clinical evidence of acute myocardial ischemia, including: (1) Symptoms of acute myocardial ischemia; (2) New ischemic electrocardiogram changes; (3) New pathological Q - wave; (4) New imaging evidence of viable myocardial loss or abnormal wall segmental motion; (5) Coronary artery thrombosis confirmed by coronary angiography, intracavitary imaging examination, or autopsy.)\n* Successfully received PPCI treatment (assessed by visual inspection or quantitative coronary angiography, with residual stenosis of the target lesion \\\u003C 20% after stent implantation or \\\u003C 50% after simple balloon dilation, and forward TIMI blood flow ≥ grade 2).\n* Signed a written informed consent form.\n\nExclusion Criteria:\n\n* Cardiogenic shock with poor response to vasoactive drugs; or uncontrolled acute left - heart failure or pulmonary edema; uncontrolled malignant arrhythmia.\n* LVEF \\\u003C 40%.\n* Currently using nicorandil, other Chinese patent medicines, and Chinese herbal decoctions, etc.\n* Unable to undergo CMR examination for various reasons.\n* Expected to be unable to complete 6 - month treatment with Guanxinning Tablets.\n* Contraindications or allergies to Guanxinning Tablets.\n* Suspected or confirmed hereditary cardiomyopathy (such as hypertrophic, dilated, obstructive cardiomyopathy, cardiac amyloidosis, hemochromatosis cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, etc.).\n* Active or chronic liver disease.\n* Renal insufficiency (eGFR \\\u003C 60ml\u002Fmin\u002F1.73m²).\n* History of previous cerebral hemorrhage.\n* History of alcohol or drug abuse.\n* Known active infection, or severe hematological, metabolic, or endocrine dysfunction.\n* Patients who have received systemic steroid or cyclosporine treatment in the past 3 months.\n* Active malignant tumor.\n* Life expectancy less than 6 months.\n* Pregnant or lactating women.\n* Already participating in other clinical studies.","80 Years",{"count":297,"type":22},70,[165],"①Research objective: In a small sample population, through the pre - experimental method, explore and evaluate the effect of Guanxinning tablets on the coronary microcirculation after primary percutaneous coronary intervention (PPCI) in patients with acute ST - segment elevation myocardial infarction (STEMI), with the change in the percentage of intramyocardial hemorrhage (IMH) in ventricular mass measured by cardiac magnetic resonance (CMR) imaging as the primary endpoint.\n\n②Research significance: The research results of this project will provide preliminary theoretical basis and methodological support for the formal randomized controlled study on evaluating the effect of Guanxinning tablets on the coronary microcirculation after PPCI in STEMI patients. It will offer new ideas for the long - term clinical treatment of STEMI patients after PPCI, and provide important theoretical support for expanding the clinical indications of Guanxinning tablets and exploring the reasons for its improvement of cardiovascular outcomes.",[301,302,303,304,305],"STEMI (ST Elevation MI)","STEMI - ST Elevation Myocardial Infarction","STEMI","CMD","Coronary Microvascular Dysfunction (CMD)",[307,308,309,310,311],"TCM","traditional chinese medicine","guanxinning tablet","CMR","intramyocardial hemorrhage","2026-05-27",{"date":170,"type":35},{"date":174,"type":22},{"date":316,"type":22},"2027-02-01",{"name":41,"class":42},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":295,"enrollmentInfo":326,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":43},"100640955","target-oriented-strategy-of-ultra-low-ldl-c-10-vs-10-139-mmoll-in-extreme-high-risk-ascvd-patients-clinical-benefit-safety-and-cost-effectiveness-assessment-100640955","NCT07615296","Target-Oriented Strategy of Ultra-Low LDL-C (\u003C1.0 vs. 1.0-1.39 mmol\u002FL) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment","Target-Oriented Strategy of Ultra-Low LDL-C Goal in Extreme-High-Risk ASCVD Patients (\u003C1.0 vs. 1.0-1.39 mmol\u002FL): Clinical Benefit, Safety and Cost-Effectiveness Assessment- A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint Adaptive Trial","TARGET-EXTREME","Inclusion Criteria:\n\n1. Aged 18-80 years, any sex.\n2. Diagnosed with ultra-high-risk ASCVD per 2023 Chinese Lipid Guidelines: either ≥2 major ASCVD events within 24 months, or 1 major ASCVD event plus ≥2 high-risk factors (diabetes, multi-vessel disease, premature CHD family history, elevated Lp(a), hypertension).\n3. LDL-C ≥1.0 mmol\u002FL after ≥4-week maximum-tolerated statin plus ezetimibe therapy, confirmed by central laboratory.\n4. Able to complete follow-up and examinations; no severe hepatic\u002Frenal dysfunction.\n5. Voluntary participation with written informed consent.\n\nExclusion Criteria:\n\n1. Hypersensitivity or intolerance to statins, ezetimibe, or PCSK9 inhibitors.\n2. Hemorrhagic stroke, active bleeding, severe trauma or major surgery within 6 months before enrollment.\n3. Malignancy (expected survival \\\u003C3 years), severe liver\u002Fkidney disease, or autoimmune disease.\n4. Cognitive impairment (MoCA \\\u003C20) or psychiatric disorders precluding assessment cooperation.\n5. Pregnant, breastfeeding, or planning pregnancy during the trial.\n6. Participation in other clinical trials or use of other lipid-lowering drugs within 3 months.\n7. Poor compliance or other conditions judged by investigators to interfere with the study.",{"count":327,"type":22},6000,[25],"The goal of this clinical trial is to learn whether an ultra-low LDL-C target (\\\u003C1.0 mmol\u002FL) can improve clinical outcomes compared with a moderately low LDL-C target (1.0-1.39 mmol\u002FL) in Chinese patients with extreme-high-risk atherosclerotic cardiovascular disease (ASCVD). It also aims to evaluate long-term safety and cost-effectiveness, and explore potential benefit subgroups and underlying mechanisms. The main questions it aims to answer are:\n\nDoes an LDL-C target \\\u003C1.0 mmol\u002FL reduce major adverse cardiovascular events (MACE-4: cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, urgent coronary revascularization) compared with a target of 1.0-1.39 mmol\u002FL?What are the long-term safety risks including cognitive decline, hemorrhagic stroke, new-onset diabetes, new malignancies and severe adverse drug reactions under different LDL-C targets?Researchers will compare participants receiving an LDL-C target \\\u003C1.0 mmol\u002FL with those receiving a target of 1.0-1.39 mmol\u002FL to see if the ultra-low LDL-C strategy provides better clinical benefit with acceptable safety and economic value.\n\nParticipants will:\n\nReceive lipid-lowering therapy following a mandatory titration-maintenance-off-target correction algorithm according to their assigned LDL-C target Undergo routine follow-up every 3 months, cognitive assessment every 6 months, and comprehensive annual re-examinations for a median of 2 years and up to 5 years Have centralized blinded lipid testing and endpoint adjudication by an independent Clinical Event Committee",[331],"Atherosclerotic Cardiovascular Disease (ASCVD)",[333],"Extreme-high-risk ASCVD, LDL-C target, Ultra-low LDL-C, Lipid-lowering therapy","2026-05-23",{"date":281,"type":35},{"date":337,"type":22},"2027-01-01",{"date":339,"type":22},"2031-12-31",{"name":41,"class":42},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":348,"targetDuration":350,"studyType":77,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":363,"locationsCount":43},"100638048","active-post-market-surveillance-of-innovative-devices-for-valvular-heart-disease-100638048","NCT07605624","Active Post-Market Surveillance of Innovative Devices for Valvular Heart Disease","An Active Post-Market Surveillance Study Assessing the Real-World Clinical Applicability, Long-Term Safety, and Effectiveness of Innovative Medical Devices for Valvular Heart Disease","Inclusion Criteria:\n\n* Patients with valvular heart disease (VHD) receiving treatment with prosthetic aortic valve replacement systems (transcatheter and surgical valves), transcatheter mitral valve edge-to-edge repair (TEER) systems, or transcatheter tricuspid valve annuloplasty systems\n* Age ≥ 18 years\n* Patients who voluntarily participate in the study and sign the informed consent form\n* Willing and able to comply with follow-up requirements",{"count":349,"type":22},5500,"1 Year","This prospective, multicenter, observational cohort study aims to establish a post-market registry framework to evaluate the real-world clinical applicability, long-term safety, and effectiveness of innovative heart valve devices in China.",[353,354,355,356],"Aortic Stenosis","Aortic Regurgitation","Mitral Regurgitation","Tricuspid Regurgitation","2026-05-18",{"date":359,"type":35},"2026-05-26",{"date":361,"type":22},"2026-05-10",{"date":124,"type":22},{"name":41,"class":42},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":211,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":387},"100621600","smartwatch-based-intervention-for-cardiovascular-health-switch-100621600","NCT07372729","Smartwatch-based Intervention for Cardiovascular Health (SWITCH)","A Smart Wearable Devices-based Comprehensive Intervention Through a Cluster Randomized Controlled Trial to Improve Cardiovascular Health in Overweight\u002FObese Individuals With Cardiometabolic Preconditions","Inclusion Criteria:\n\n1. Age \\>= 18 years, no gender restriction;\n2. Overweight and obesity: Body Mass Index (BMI) 24.0-32.4 kg\u002Fm\\^2, or waist circumference \\>= 90 cm for males and \\>= 85 cm for females;\n3. Presence of at least one metabolic high-risk state among prehypertension, prediabetes, or borderline elevated blood lipids, and without a diagnosis of hypertension, diabetes mellitus, or dyslipidemia:\n\n(1) Prehypertension: Systolic blood pressure (SBP) 130-139 mmHg and\u002For diastolic blood pressure (DBP) 80-89 mmHg, without regular use of antihypertensive medication in the past month; (2) Prediabetes: Fasting blood glucose (FBG) 6.1-6.9 mmol\u002FL, or glycated hemoglobin (HbA1c) 5.7%-6.4%, without regular use of hypoglycemic medication in the past month; (3) Borderline elevated blood lipids: Total cholesterol (TC) 5.2-6.1 mmol\u002FL, or low-density lipoprotein cholesterol (LDL-C) 3.4-4.0 mmol\u002FL, or triglycerides (TG) 1.7-2.2 mmol\u002FL, or non-high-density lipoprotein cholesterol (non-HDL-C) 4.1-4.8 mmol\u002FL, without regular use of lipid-lowering medication in the past month; 4. Local permanent residents who will reside in the area for at least 12 month after enrollment; 5. Have basic reading, writing, and comprehension abilities; proficient in using internet-connected smartphones; able to independently complete basic operations of the application; 6. Written informed consent provided.\n\nExclusion Criteria:\n\n1. Secondary obesity diagnosed by doctors in secondary or higher-level medical institutions;\n2. Cardiovascular and cerebrovascular diseases, including myocardial infarction, stroke, heart failure, arrhythmia; or having received coronary intervention therapy, cardiac surgery, etc.; or with a 10-year high risk of cardiovascular disease;\n3. Diseases seriously affecting survival, such as malignant tumors, AIDS, hepatic and renal failure;\n4. Pregnancy, lactation period, or women who may become pregnant within one year;\n5. History of severe neuropsychiatric diseases with potential cognitive or communication impairments, such as dementia, Alzheimer's disease, Parkinson's syndrome;\n6. Individuals with limited daily mobility;\n7. Individuals undergoing or planning to receive weight loss through surgery, medication, or other methods;\n8. Currently participating in other lifestyle intervention-related trials.",{"count":372,"type":22},1400,[25],"This study aims to employ a cluster randomized controlled trial to evaluate the effectiveness of an mHealth-Based Multi-faceted Cardiovascular Health Intervention Model among Overweight\u002FObese Individuals with Cardiometabolic Preconditions, thereby providing theoretical foundations and practical guidance for the prevention and management of this population.",[376,377,378,379],"Prehypertension","Borderline Dyslipidemia","Overweight , Obesity","Prediabetes",{"date":381,"type":35},"2026-05-14",{"date":383,"type":35},"2026-03-24",{"date":385,"type":22},"2027-03-15",{"name":41,"class":42},3,{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":43},"100537175","standby-cannulated-ecmo-for-high-risk-percutaneous-coronary-intervention-100537175","NCT06274411","Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention","Standby Cannulated ECMO Versus Prophylactic ECMO In Patients Undergoing High-Risk Percutaneous Coronary Intervention","ECMO-READY","Inclusion Criteria:\n\n1. Clinicians decide to perform PCI during ECMO support.\n2. Age of ≥18\n3. Patient presents with a compromised ejection fraction of less than 35% or at risk of hemodynamic deterioration, or intervention on the last patent coronary conduit or an unprotected left main artery, or complex 3-vessel disease (SYNTAX score of ≥33)\n4. Informed consent\n\nExclusion Criteria:\n\n1. Subject in cardiogenic shock(need inotrope, pressor or mechanical support to maintain SBP \\>90mmHg)\n2. Presence of moderate to severe aortic insufficiency\n3. Severe peripheral vascular disease\n4. creatinine≥4mg\u002FdL\n5. Liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3x ULN\n6. History of recent (within 1 month) stroke or TIA\n7. Abnormal coagulation(defined as platelet count ≤50000\u002Fmm3 or Fibrinogen ≤1.50g\u002FL)\n8. Allergy or intolerance to heparin, aspirin, ADP receptor inhibitors, or documented heparin induced thrombocytopenia.",{"count":397,"type":22},176,[25],"The goal of this multicenter, randomized trial is to compare standby cannulated ECMO versus prophylactic ECMO in patients undergoing high-risk percutaneous coronary intervention (PCI). The main question it aims to answer is :\n\n• If standby cannulated ECMO as compared with prophylactic ECMO will improve the outcomes in patients undergoing high-risk PCI",[401,402],"ECMO","High-risk PCI",[401,404],"PCI",{"date":406,"type":35},"2026-05-13",{"date":408,"type":35},"2025-03-21",{"date":410,"type":22},"2026-12-01",{"name":41,"class":42},{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":295,"enrollmentInfo":419,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":43},"100584152","prediction-of-lvar-and-mace-in-stemi-though-plasma-multiomics-analysis-100584152","NCT06885619","Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis","Prediction of Left Ventricular Adverse Remodeling and Major Adverse Cardiovascular Events in Patients With Acute ST-segment Elevation Myocardial Infarction Though Plasma Multiomics Analysis","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years.\n2. Definite diagnosis of STEMI according to ESC\u002FACC guidelines:\n\n   * Chest pain lasting \\>30 minutes, and\n   * ST-segment elevation in at least two contiguous leads: ≥0.2 mV in leads V2-V3 (≥0.2 mV for men, ≥0.15 mV for women) or ≥0.1 mV in other leads, or new-onset left bundle branch block.\n3. Reperfusion therapy: Symptom onset to first medical contact ≤12 hours, and successful primary PCI (culprit vessel opened, post-procedure TIMI flow grade 3).\n4. First STEMI (no prior history of myocardial infarction).\n5. Left ventricular ejection fraction (by echocardiography within 24-48 hours after admission) ≥35%.\n6. Informed consent: Signed informed consent obtained, with willingness to undergo serial blood sampling and echocardiographic follow-up.\n\nExclusion Criteria:\n\n1. Non-atherosclerotic MI: coronary embolism, spasm, aortic dissection, myocarditis, Takotsubo.\n2. Severe comorbidities:\n\n   * Prior HF (NYHA ≥II);\n   * Severe CKD (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² or dialysis);\n   * Severe liver disease (Child-Pugh B\u002FC);\n   * Active malignancy (life expectancy \\\u003C1 year);\n   * Severe hematologic disorders (thrombocytopenia, coagulopathy, active bleeding).\n3. Fibrinolysis-followed-by-PCI.\n4. Primary PCI complications:\n\n   * No-reflow\u002Fslow-flow (final TIMI \\\u003C2);\n   * Cardiogenic shock or mechanical complication within 7 days;\n   * In-hospital repeat revascularization.\n5. Inability to complete 6-month follow-up.\n6. Factors affecting blood sampling\u002Fexosome\u002Fimmune\u002Fproteome assays:\n\n   * Blood transfusion within 1 month;\n   * Known hemolytic disorder;\n   * Inadequate venous access.\n7. Pregnancy or lactation.",{"count":213,"type":22},"To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.",[422,423,424,425,426],"Left Ventricular Remodeling","Plasma Multi-Omics","Acute ST-segment Elevation Myocardial Infarction","Immunomics","Major Adverse Cardiovascular Events","2026-05-07",{"date":122,"type":35},{"date":430,"type":35},"2025-05-01",{"date":432,"type":22},"2027-12-31",{"name":41,"class":42},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":453,"leadSponsor":455,"locationsCount":43},"100636718","low-dose-colchicine-for-cabg-graft-failure-prevention-100636718","NCT07569328","Low-dose Colchicine for CABG Graft Failure Prevention","Low-dose Colchicine for CABG Graft Failure Prevention: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Be male or female, aged 18 years or older;\n2. Within 3 days after successful isolated coronary artery bypass grafting (CABG);\n3. Sign informed consent;\n\nExclusion Criteria:\n\n1. Severe valvular heart disease requiring concomitant or staged valvular surgery;\n2. History of non-skin cancer in the past 3 years;\n3. Inflammatory bowel disease or chronic diarrhea;\n4. Neuromuscular diseases or non-transient creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction);\n5. Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities (Hemoglobin \\\u003C100g\u002FL or hematocrit \\\u003C 30% or \\> 52% or white blood cell count \\\u003C 3×109\u002FL or platelet count \\\u003C 100×109\u002FL);\n6. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m² (based on the CKDEPI formula);\n7. Serum alanine aminotransferase and\u002For aspartate aminotransferase levels greater than 2 times the upper limit of the normal range, accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders (INR\\>1.5) (except for elevated glutamic oxalacetic transaminase associated with myocardial infarction);\n8. Decline in cognitive function due to inability to perform basic activities of daily living independently;\n9. Drug or alcohol abuse;\n10. Other immunosuppressive therapies already in existence or planned;\n11. Other causes require long-term colchicine treatment;\n12. History of clear or suspected colchicine allergy;\n13. Strong CYP3A4 or P-glycoprotein inhibitors (such as cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) have been used and no other alternative drugs can be used.",{"count":442,"type":22},622,[25],"This study aims to evaluate whether daily low-dose colchicine (0.5 mg), administered in addition to the standard secondary prevention regimen recommended in clinical guidelines after coronary artery bypass grafting (CABG), can further prevent graft failure after CABG through a prospective, randomized, double-blind, placebo-controlled clinical trial.",[446,447,448],"CAD - Coronary Artery Disease","CABG","Colchicine","2026-04-29",{"date":451,"type":35},"2026-05-06",{"date":245,"type":22},{"date":454,"type":22},"2029-09-01",{"name":41,"class":42},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":462,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":23,"phases":466,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":478},"100620074","digital-remote-management-versus-usual-care-for-optimization-of-guideline-directed-medical-therapy-in-patients-with-heart-failure-and-reduced-ejection-fraction-a-multicentre-randomised-controlled-trial-digicare-hfref-100620074","NCT07352891","Digital Remote Management Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction: a Multicentre, Randomised, Controlled Trial (DigiCare-HFrEF)","Digital Remote Management for Care and Continuous Optimization Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction (DigiCare-HFrEF): a Multicentre, Randomised, Controlled Trial","DigiCare-HFrEF","Inclusion Criteria:\n\n1. Adults aged ≥18 years.\n2. Hospitalised at a secondary or tertiary hospital with established heart failure care capacity.\n3. Diagnosed with HFrEF within the past 3 months according to the 2022 ACC\u002FAHA\u002FHFSA guideline diagnostic pathway, including: LVEF ≤40% by echocardiography; typical heart-failure symptoms and\u002For signs; and exclusion of non-HF causes of symptoms.\n4. Not optimized on guideline-directed medical therapy (GDMT) at enrollment, defined as at least two of the following four foundational drug classes not initiated or administered at \\\u003C50% target dose.\n5. Written informed consent provided.\n\nExclusion Criteria:\n\n1. Absolute contraindication to heart failure pharmacotherapy.\n2. History of heart transplantation or currently on a transplant waiting list.\n3. Receiving or planning implantation of a left ventricular assist device.\n4. Pregnant or breastfeeding women.\n5. Organ transplantation within the past 12 months.\n6. Unable to use the remote management platform as required (e.g., cognitive impairment or lack of caregiver support).\n7. Unable to perform blood pressure or body-weight monitoring (e.g., severe limb disability).\n8. Unable to express willingness or comply with follow-up requirements (e.g., unable to use internet-enabled devices).\n9. Any other condition judged by the investigator to make the patient unsuitable for participation.",{"count":465,"type":22},252,[25],"DigiCare-HFrEF is an investigator-initiated, multicentre, randomised, open-label, endpoint-blinded, superiority trial designed to evaluate whether a structured digital remote-management platform can optimise guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) after hospital discharge. Eligible adults (≥18 years) with a confirmed diagnosis of HFrEF within the past 3 months (left ventricular ejection fraction ≤40%) who are not optimally treated with GDMT-defined as at least two of the four foundational drug classes (ACEi\u002FARB or ARNi, β-blocker, MRA, SGLT2 inhibitor) either not initiated or prescribed at \\\u003C50% of the target dose-will be randomly assigned in a 1:1 ratio to digital remote management or usual care. In the intervention arm, patients will report symptoms and key physiologic measures (e.g., blood pressure, heart rate, and body weight) via the platform; an algorithm will perform risk stratification and generate GDMT optimisation suggestions and decongestion prompts, as well as a comprehensive management for core health metrics, which are reviewed and confirmed by clinicians before implementation. The primary endpoint is the change in GDMT score from baseline to 3 months (ΔGDMT).",[469],"Heart Failure With Reduced Ejection Fraction","2026-04-21",{"date":472,"type":35},"2026-04-24",{"date":474,"type":35},"2026-02-26",{"date":476,"type":22},"2026-07",{"name":41,"class":42},6,{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":211,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":496,"locationsCount":4},"100634936","development-and-clinical-validation-of-key-technologies-for-non-invasive-breath-metabolic-fingerprinting-for-large-scale-population-lipid-screening-100634936","NCT07546162","Development and Clinical Validation of Key Technologies for Non-invasive Breath Metabolic Fingerprinting for Large-scale Population Lipid Screening","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n1. Patients with lung cancer, asthma, chronic obstructive pulmonary disease, cystic fibrosis, or acute respiratory distress syndrome\n2. Women during pregnancy or breastfeeding\n3. Patients with chronic kidney disease (GFR \\\u003C60 ml\u002Fmin) or liver cirrhosis\n4. Individuals unable to cooperate in collecting exhaled breath samples",{"count":486,"type":22},280,"This study collects exhaled breath condensate samples from healthy populations and hyperlipidemic populations, analyzes the characteristics of the exhaled metabolic lipid profile for early identification of people with abnormal blood lipids, verifies the feasibility and accuracy of a new gas detection method for screening abnormal blood lipids, and explores a simple, fast, and non-invasive method for screening abnormal blood lipids.",[489],"Hyperlipidemia","2026-04-20",{"date":492,"type":35},"2026-04-22",{"date":494,"type":22},"2026-04-02",{"date":242,"type":22},{"name":41,"class":42},{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":295,"enrollmentInfo":505,"targetDuration":4,"studyType":23,"phases":507,"briefSummary":508,"conditions":509,"keywords":511,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":43},"100634565","safety-and-efficacy-of-conscious-sedation-versus-general-anesthesia-in-pulsed-field-ablation-for-paroxysmal-atrial-fibrillation-100634565","NCT07541339","Safety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation","Safety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation: A Randomized Controlled Trial","SEDATE-PFA","Inclusion Criteria:\n\n* Aged 18 to 80 years\n* Diagnosed with paroxysmal atrial fibrillation\n* No prior history of catheter ablation for atrial fibrillation\u002Fatrial flutter\n* Scheduled to undergo pulsed-field ablation\n* Provide written informed consent for study participation and be able to complete all scheduled follow-up assessments\n\nExclusion Criteria:\n\n* Obstructive sleep apnea-hypopnea syndrome (OSAHS)\n* Complicated with severe chronic obstructive pulmonary disease (COPD), asthma or other respiratory system diseases\n* Body mass index (BMI) \\>30 kg\u002Fm² or \\\u003C20 kg\u002Fm²\n* Preoperative pulse oxygen saturation (SpO₂) \\\u003C93%\n* Anticipated difficult airway\n* Intolerance to general anesthesia (American Society of Anesthesiologists \\[ASA\\] physical status ≥Ⅳ)\n* Current left ventricular ejection fraction (LVEF) ≤40% or New York Heart Association (NYHA) functional class Ⅲ-Ⅳ\n* Acute coronary syndrome within 3 months\n* Within 3 months after percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) or other cardiac\u002Fvascular surgeries\n* Moderate\u002Fsevere stenosis or severe regurgitation of aortic or mitral valve\n* Acute cerebrovascular disease within 1 month\n* Severe hepatic insufficiency (Child-Pugh Class C)\n* Estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73m² or on dialysis\n* History of chronic heavy alcohol consumption\n* History of substance abuse\n* Hypersensitivity to any medications used in the study protocol\n* Pregnancy or lactation\n* Concurrent participation in other interventional clinical trials\n* Other conditions deemed unsuitable for study participation by the investigators",{"count":506,"type":22},224,[25],"The goal of this clinical trial is to compare the safety and efficacy of conscious sedation and general anesthesia in patients with paroxysmal atrial fibrillation undergoing their first pulsed-field ablation (PFA) procedure. It will also establish a scalable conscious sedation protocol for PFA. The main questions it aims to answer are:\n\n1. Does conscious sedation reduce the incidence of the composite safety endpoint (persistent hypotension or hypoxemia for more than 60 seconds intraoperatively) compared with general anesthesia?\n2. What are the differences in perioperative indicators and adverse events between the two anesthetic strategies in PFA for paroxysmal atrial fibrillation? Researchers will randomly assign eligible patients to a conscious sedation group or a general anesthesia group at a 1:1 ratio to compare the safety and efficacy of the two anesthetic approaches.\n\nParticipants will:\n\n1. Receive the assigned anesthetic strategy combined with standardized PFA procedure\n2. Complete intraoperative vital sign and related index monitoring\n3. Undergo follow-up visits at 12-24 hours, 30 days and 90 days after surgery for relevant index assessment and adverse event recording",[510],"Atrial Fibrillation (Paroxysmal)",[512,513,514,515,516,517],"Paroxysmal atrial fibrillation","Pulsed-field ablation","Conscious sedation","General anesthesia","Efficacy","Safety","2026-04-14",{"date":470,"type":35},{"date":521,"type":22},"2026-04-01",{"date":523,"type":22},"2027-03-01",{"name":41,"class":42},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":535,"briefSummary":536,"conditions":537,"keywords":539,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":43},"100630679","peri-procedural-hydration-to-prevent-acute-kidney-injury-after-pulsed-field-ablation-for-atrial-fibrillation-100630679","NCT07490808","Peri-procedural Hydration to Prevent Acute Kidney Injury After Pulsed Field Ablation for Atrial Fibrillation","Peri-procedural Hydration to Prevent Acute Kidney Injury After Pulsed Field Ablation for Atrial Fibrillation: A Single-Center, Open-Label, Randomized Controlled Trial","HYDRATE-PFA","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Age ≥18 years.\n* Symptomatic paroxysmal atrial fibrillation (AF) or persistent AF:\n\n  1. Paroxysmal AF: AF that terminates spontaneously or with intervention within 7 days of onset, and meets both of the following:\n\n     1. At least 2 symptomatic paroxysmal AF episodes within 6 months before enrollment;\n     2. At least 1 documented AF episode by electrocardiogram (ECG) or Holter monitoring within 12 months before enrollment.\n  2. Persistent AF: AF lasting \\>7 days and ≤365 days, and meets both of the following:\n\n     1. At least 1 symptomatic persistent AF episode within 6 months before enrollment;\n     2. Persistent AF documented within 12 months before enrollment by either Holter monitoring or 2 ECGs obtained at least 7 days apart.\n* Failure of antiarrhythmic drug (AAD) therapy, defined as inadequate efficacy and\u002For intolerance to at least 1 Class I or Class III AAD.\n* Planned to undergo pulsed field ablation (PFA).\n* Willing and able to provide written informed consent.\n* Willing and able to comply with study procedures, including in-hospital assessments and 30-day and 90-day follow-up.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n* AF due to a reversible cause, such as hyperthyroidism or perioperative\u002Fcardiothoracic surgery-related AF.\n* No oral anticoagulation for at least 3 weeks before ablation.\n* Intracardiac thrombus.\n* Contraindication to anticoagulant therapy or iodinated contrast media.\n* Significant valvular heart disease, including moderate or severe aortic stenosis, severe aortic regurgitation, moderate or severe mitral stenosis, or severe mitral regurgitation.\n* Myocardial infarction within 3 months before enrollment.\n* Cardiac surgery within 3 months before enrollment.\n* New York Heart Association (NYHA) class III or IV congestive heart failure.\n* Left ventricular ejection fraction (LVEF) \\\u003C35%.\n* Hypertrophic cardiomyopathy.\n* Severe liver disease (Child-Pugh score \\>7).\n* Stage 4 or 5 chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* History of kidney transplantation.\n* Need for renal replacement therapy (RRT) at enrollment or any history of prior RRT.\n* Intravascular iodinated contrast administration within 7 days before enrollment.\n* Active systemic infection.\n* Known pregnancy or breastfeeding.\n* Participation in another clinical trial that may affect the results of this study.\n* Unwillingness or inability to comply with study procedures and follow-up, including participants considered by the investigator to be at substantial risk for poor adherence.",{"count":534,"type":22},290,[25],"PFA is an emerging non-thermal ablation technology with favorable procedural safety; however, recent studies have raised concerns about peri-procedural hemolysis and subsequent AKI after PFA. This study is a single-center, open-label, randomized controlled trial designed to evaluate whether standardized peri-procedural intravenous hydration can reduce the risk of acute kidney injury (AKI) after pulsed field ablation (PFA) for atrial fibrillation (AF).\n\nEligible adult patients with symptomatic paroxysmal or persistent AF scheduled for PFA will be randomly assigned in a 1:1 ratio to either a standardized hydration strategy or a control strategy without routine prophylactic hydration. The hydration group will receive 0.9% saline at 2 mL\u002Fkg\u002Fh from entry into the electrophysiology laboratory until 12 hours after the procedure, while the control group will receive no routine preventive hydration and will be treated with fluids only if clinically indicated.\n\nThe primary outcome is any in-hospital AKI defined according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Secondary endpoints include in-hospital AKI severity by KDIGO stage, in-hospital persistent moderate-to-severe AKI, in-hospital renal replacement therapy, changes in renal function after the procedure, and clinical outcomes through 30 and 90 days, including all-cause death, persistent AKI, renal replacement therapy, all-cause rehospitalization, and composite major adverse events.",[108,538],"Acute Kidney Injury",[540,113,541,542],"Pulsed field ablation","Acute kidney injury","Hydration",{"date":544,"type":35},"2026-04-17",{"date":546,"type":35},"2026-03-20",{"date":548,"type":22},"2026-10",{"name":41,"class":42},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":23,"phases":560,"briefSummary":561,"conditions":562,"keywords":569,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":586,"locationsCount":43},"100633038","llm-based-intelligent-health-management-assistant-in-life-cycle-health-management-of-cardiac-surgery-patients-100633038","NCT07521488","LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients","Application of Large Language Model-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Patients After Cardiac Surgery: A Prospective Randomized Controlled Study","cFT-LLM","Inclusion Criteria:\n\n1. Aged 18 years or older, any sex\n2. Underwent cardiac surgery at the Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, including but not limited to: coronary artery bypass grafting (CABG), heart valve replacement or repair (aortic valve, mitral valve, or tricuspid valve surgery), great vessel surgery (aortic dissection or aortic aneurysm repair), congenital heart disease correction, or cardiac assist device implantation\n3. Clinically stable after surgery and eligible for hospital discharge\n4. Has access to a smartphone and is capable of independently operating a mobile application, or has a family member available to assist with operation\n5. Voluntarily participates in the study, understands and signs the informed consent form, and is able to comply with the study protocol requirements\n\nExclusion Criteria:\n\n1. Postoperative intensive care unit (ICU) stay exceeding 30 days, or presence of severe uncontrolled postoperative complications such as persistent infection or multi-organ failure\n2. Life expectancy less than 12 months due to advanced malignancy or end-stage organ failure\n3. Severe cognitive impairment, psychiatric disorder, or inability to understand and use a mobile application without available caregiver assistance\n4. Heart transplant recipient\n5. Currently participating in another interventional clinical study\n6. Anticipated inability to complete 12-month follow-up",{"count":559,"type":22},500,[25],"This is a single-center, prospective, randomized, open-label, parallel-controlled clinical study to evaluate the effectiveness of a large language model (LLM)-based intelligent health management assistant in the life-cycle health management of patients after cardiac surgery. A total of 500 adult patients who undergo cardiac surgery (including coronary artery bypass grafting, heart valve surgery, great vessel surgery, congenital heart disease correction, and other cardiac procedures) at Beijing Anzhen Hospital will be randomly assigned in a 1:1 ratio to an intervention group or a control group, stratified by age (\\\u003C65 vs ≥65 years) and surgery type. The intervention group will use the LLM-based mobile health management application in addition to standard postoperative care, while the control group will receive standard postoperative care alone. The application integrates multimodal clinical data into a personalized health profile and provides surgery-type-specific postoperative management recommendations, medication adherence reminders, complication early warning, and cardiac rehabilitation guidance. The primary outcome is the composite endpoint of major adverse cardiac and cerebrovascular events (MACCE), defined as all-cause death, non-fatal myocardial infarction, non-fatal stroke, or unplanned cardiovascular reoperation\u002Freintervention, within 12 months after randomization. Secondary outcomes include health-related quality of life (EQ-5D-5L), cardiovascular rehospitalization rate, medication adherence (MMAS-8), postoperative complication rate, and cardiac rehabilitation achievement rate. Follow-up visits are scheduled at 1, 3, 6, 9, and 12 months post-randomization.",[563,564,565,566,567,568],"Coronary Artery Bypass Grafting","Heart Valve Disease","Aortic Aneurysm","Aortic Dissection","Congenital Heart Disease","Cardiac Surgical Procedures",[570,571,572,573,574,575,576,577,578,579],"Large Language Model","Artificial Intelligence","Cardiac Surgery","Postoperative Health Management","Digital Health","Medication Adherence","Cardiac Rehabilitation","MACCE","Mobile Health Application","Personalized Health Management","2026-04-08",{"date":582,"type":35},"2026-04-13",{"date":584,"type":22},"2026-05-01",{"date":432,"type":22},{"name":41,"class":42},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":595,"enrollmentInfo":596,"targetDuration":4,"studyType":23,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":43},"100604518","arch-clamping-technique-under-mild-hypothermia-in-treating-with-acute-type-a-aortic-dissection-100604518","NCT07150559","Arch-Clamping Technique Under Mild Hypothermia in Treating With Acute Type A Aortic Dissection","Arch-Clamping Technique Under Mild Hypothermia in Treating With Acute Type A Aortic Dissection: Study Protocol for a Multicenter, Three-arm, Open-label, Randomized, Parallel-controlled Trial","AHEAD","Inclusion Criteria:\n\n1. Aortic CTA confirmed as ATAAD according to the 2022 ACC\u002FAHA Guideline for the Diagnosis and Management of Aortic Disease;\n2. Adult patients (18-70 years) weighing 50-120 kg;\n3. Time interval between the onset of symptoms and operation is less than 14 days;\n4. Indications for total aortic arch replacement are available;\n5. Signed informed consent and availability for follow-up.\n\nExclusion Criteria:\n\n1. History of chronic renal failure, hepatocirrhosis, and hepatic insufficiency;\n2. Severe gastrointestinal complications of non-aortic dissection, such as mesenteric ischemia, gastrointestinal bleeding, hepatopancreaticobiliary dysfunction, and intestinal obstruction;\n3. History of severe cerebral infarction (with cerebral infarction sequels);\n4. Preoperative intubation or unconsciousness;\n5. Inflammatory aortic diseases, such as Takayasu arteritis and Behçet's disease, etc;\n6. History of infectious aortic diseases;\n7. History of cardiac and aortic surgery;\n8. History of malignancy or previous radiotherapy;\n9. Pregnant or feeding women, or anyone planning to reproduce during the test period;\n10. Without an informed consent signature;\n11. Participating in any other clinical trial;\n12. Having other causes not eligible for operation.","70 Years",{"count":597,"type":22},306,[25],"The study is a multicenter, three-arm, open-label, randomized, parallel-controlled trial, which plans to enroll 306 participants diagnosed with acute type A aortic dissection (ATAAD) from 7 hospitals in China. All patients receive total arch replacement (TAR) combined with frozen elephant trunk (FET) implantation and are randomized to Group 1 (arch-clamping technique under mild hypothermia), Group 2 (arch-clamping technique under moderate hypothermia) and Group 3 (Sun's procedure using bilateral antegrade cerebral perfusion) in the ratio of 1:1:1. After a 1-year follow-up, the validity and safety of the mild hypothermic arch-clamping technique for ATAAD was evaluated via the incidence of major adverse events including death, renal replacement therapy, stroke, and paraplegia, as well as times of circulatory arrest, cardiopulmonary bypass, and mechanical ventilation, and length of ICU stay.",[601,602,603,604,605],"Acute Type A Aortic Dissection","Hypothermia","Total Aortic Arch Replacement","Frozen Elephant Trunk","Bilateral Antegrade Cerebral Perfusion",{"date":607,"type":35},"2026-04-06",{"date":609,"type":35},"2026-02-03",{"date":611,"type":22},"2028-02-28",{"name":41,"class":42},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":295,"enrollmentInfo":619,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":622,"conditions":623,"keywords":625,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":629,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":635},"100619231","helium-free-magnetocardiography-guided-therapy-for-stable-coronary-artery-disease---a-randomized-controlled-trial-100619231","NCT07341932","Helium-free Magnetocardiography Guided Therapy for Stable Coronary Artery Disease - A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years, regardless of gender.\n2. Patients with stable coronary artery disease (CAD).\n3. Coronary computed tomography angiography (CCTA) shows at least one major coronary vessel (diameter ≥2.5 mm) with 50-90% stenosis. Patients with 50-69% stenosis must have typical or atypical angina; for those with 70-90% stenosis, the presence of chest pain symptoms is not required.\n\n   \\*Note: Chest pain is characterized by the following three features:\\* \\*(1) Chest discomfort lasting less than 15 minutes;\\* \\*(2) Precipitated by physical exertion or emotional stress;\\* \\*(3) Relieved by rest or nitrates.\\* \\*Based on these, angina is classified as:\\*\n   * \\*Typical angina: all 3 features are present;\\*\n   * \\*Atypical angina: 2 features are present;\\*\n   * \\*Non-anginal chest pain: 1 or no feature is present.\\*\n4. Willing to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Previous myocardial infarction, PCI, CABG, or coronary angiography indicating stenosis ≥50% in a major vessel.\n2. CCTA indicating left main coronary artery stenosis \\>50% and\u002For three-vessel disease.\n3. History of cardiac dysfunction (≥ NYHA Class III), severe congenital heart disease, valvular heart disease, or cardiomyopathy.\n4. Complex arrhythmias, such as frequent atrial premature beats, ventricular premature beats, atrial fibrillation, atrial flutter, etc.\n5. History of metal implant placement (including mechanical valves, pacemakers, orthopedic internal fixation plates, drug pumps, etc.).\n6. Claustrophobia.\n7. Severe thoracic deformity.\n8. Active bleeding.\n9. Any disease with an expected survival of less than 1 year.\n10. Completion of any of the following tests prior to enrollment: exercise ECG, stress echocardiography, stress SPECT, or stress CMR.\n11. Any other condition where the investigator considers the patient unsuitable for this study.",{"count":620,"type":22},1312,[25],"This rigorously designed randomized controlled trial aims to investigate whether Magnetocardiography (MCG) can optimize the clinical pathway, improve quality of life, and reduce healthcare costs in patients with stable coronary artery disease (SCAD) within real-world clinical settings, thereby generating evidence for the future application of MCG in clinical decision-making pathways.\n\nStable CAD patients with at least one major coronary vessel showing 50%-90% stenosis on coronary CTA will be enrolled based on predefined criteria. Stratified by study center and using a central web-based randomization system, participants will be allocated in a 1:1 ratio to either the \\*\\*MCG-guided group\\*\\* (where treatment recommendations for invasive coronary angiography \\[ICA\\] or optimal medical therapy are based on MCG results) or the \\*\\*conventional management group\\*\\* (where treatment strategy is based on stenosis severity, pre-test probability, and functional test results).\n\nThe study will proceed with the following evaluations:\n\n1. Compare the proportion of patients with non-obstructive coronary artery disease on planned ICA performed within 90 days between the two groups, testing the hypothesis that this proportion is lower in the MCG-guided group.\n2. Conduct telephone follow-ups at 90 days, 6 months, and 12 months post-enrollment to compare between-group differences in the rate of Major Adverse Cardiovascular Events (MACE), Seattle Angina Questionnaire (SAQ) scores, and total healthcare expenditures during the follow-up period.",[624],"Stable Coronary Artery Disease CAD",[626,627,628],"Stable coronary artery disease CAD","MCG","Randomized Controlled Trial",{"date":494,"type":35},{"date":631,"type":35},"2026-03-17",{"date":633,"type":22},"2027-12-01",{"name":41,"class":42},5,""]